FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutics and represents an injectable form of 5α-androstane-3β,5,6β-triol containing a liquid injectable form, containing a solvent, or a solid injectable form containing at least one soluble additive with the above at least one soluble additive containing hydroxypropyl-β-cyclodextrine.
EFFECT: invention provides preparing the stable injectable form of 5α-androstane-3β,5,6β-triol.
10 cl, 7 ex, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| NEUROPROTECTIVE AGENTS AND THEIR APPLICATION | 2015 |
|
RU2672264C2 |
| CRYSTALLINE FORMS OF 5α-ANDROSTANE-3β,5,6β-TRIOL AND METHODS FOR PRODUCTION THEREOF | 2012 |
|
RU2608894C2 |
| USING 5?-ANDROSTANE-3(,5,6(-TRIOL FOR PREPARING NEUROPROTECTIVE DRUGS | 2011 |
|
RU2541093C2 |
| INCLUSION COMPLEXES OF BUTYLPHTHALIDE WITH CYCLODEXTRIN OR ITS DERIVATIVES, METHOD FOR THEIR PREPARING AND THEIR USING | 2002 |
|
RU2285696C2 |
| METHOD FOR GLIBENCLAMIDE PHARMACEUTICAL COMPOSITION PREPARATION IN FORM OF INJECTION SOLUTION | 2016 |
|
RU2615368C1 |
| COMPOSITION FOR PARENTERAL ADMINISTRATION CONTAINING SIPONIMOD | 2018 |
|
RU2803937C2 |
| DERIVATIVES OF ANDROSTANE SUBSTITUTED AT 16-POSITION WITH QUATERNARY AMMONIUM GROUP, PHARMACEUTICAL COMPOSITION | 1993 |
|
RU2124021C1 |
| ANTITUMOUR MEDICATION | 2006 |
|
RU2410389C2 |
| STEROID COMPOUNDS (VARIANTS), PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT OF PATIENTS WITH NERVOUS DISORDERS (VARIANTS) AND METHOD OF ANESTHESIA INDUCTION IN ANIMAL | 1995 |
|
RU2176248C2 |
| APPLICATION OF COMPOUNDS FOR PRODUCING MEDICINAL PRODUCT FOR TREATING HEMORRHAGIC STROKE | 2018 |
|
RU2752090C1 |
